PROTHENA CORPORATION PUBLIC LIMITED COMPANY Restructuring and Related Cost, Cost Incurred to Date
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) had Restructuring and Related Cost, Cost Incurred to Date of $28.30 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Restructuring and Related Activities › Restructuring and Related Cost, Expected Cost
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2026-08-06
- 2026-06-30: Restructuring and Related Cost, Cost Incurred to Date $28.30M.
- 2026-03-31: Restructuring and Related Cost, Cost Incurred to Date $25.80M.
- 2025-12-31: Restructuring and Related Cost, Cost Incurred to Date $30.10M.
- 2025-09-30: Restructuring and Related Cost, Cost Incurred to Date $33.10M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2026-06-30 | $28.30M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $25.80M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $30.10M 10-K · filed 2026-02-27 |
| 2025-09-30 | $33.10M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $32.60M 10-Q · filed 2025-08-04 |
| 2020-12-31 | $16.10M 10-K · filed 2021-02-26 |
| 2019-12-31 | $16.10M 10-K · filed 2020-03-03 |
| 2019-09-30 | $16.10M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $16.10M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $16.10M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $16.10M 10-K · filed 2019-03-15 |
| 2018-09-30 | $17.70M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $20.90M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |